ADMA Biologics Inc

1.20+0.0200+1.69%Vol 2.13M1Y Perf -48.72%
Sep 15th, 2021 16:00 DELAYED
BID1.19 ASK1.20
Open1.19 Previous Close1.18
Pre-Market1.18 After-Market-
 -0.02 -1.67%  - -
Target Price
7.00 
Analyst Rating
Strong Buy 1.17
Potential %
483.33 
Finscreener Ranking
★★★★★     58.44
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     51.34
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     55.37
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
2.55 
Earnings Rating
Sell
Market Cap159.32M 
Earnings Date
4th Nov 2021
Alpha-0.02 Standard Deviation0.17
Beta1.18 

Today's Price Range

1.171.21

52W Range

1.153.11

5 Year PE Ratio Range

-2.40-3.60

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.84%
1 Month
-16.67%
3 Months
-33.33%
6 Months
-43.13%
1 Year
-48.72%
3 Years
-80.83%
5 Years
-79.31%
10 Years
-

TickerPriceChg.Chg.%
ADMA1.200.02001.69
AAPL149.030.91000.61
GOOG2 904.1236.00001.26
MSFT304.825.03001.68
XOM56.421.84003.37
WFC46.640.59001.28
JNJ165.420.62000.38
FB373.92-2.6100-0.69
GE102.161.78001.77
JPM158.161.09000.69
Financial StrengthValueIndustryS&P 500US Markets
3.60
9.40
0.47
0.91
-4.80
Leverage Ratio 2.30
ProfitabilityValueIndustryS&P 500US Markets
-16.30
-104.90
-96.60
-221.30
-
RevenueValueIndustryS&P 500US Markets
58.11M
0.44
33.57
36.02
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.15-0.150.00
Q01 2021-0.17-0.165.88
Q04 2020-0.17-0.20-17.65
Q03 2020-0.21-0.199.52
Q02 2020-0.19-0.23-21.05
Q01 2020-0.13-0.26-100.00
Q04 2019-0.20-0.1810.00
Q03 2019-0.22-0.1913.64
Earnings Per EndEstimateRevision %Trend
9/2021 QR-0.15-7.14Negative
12/2021 QR-0.13-8.33Negative
12/2021 FY-0.59-3.51Negative
12/2022 FY-0.34-9.68Negative
Next Report Date4th Nov 2021
Estimated EPS Next Report-0.15
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume2.13M
Shares Outstanding132.77M
Shares Float109.16M
Trades Count3.36K
Dollar Volume7.83M
Avg. Volume4.76M
Avg. Weekly Volume3.24M
Avg. Monthly Volume4.49M
Avg. Quarterly Volume3.23M

ADMA Biologics Inc (NASDAQ: ADMA) stock closed at 1.2 per share at the end of the most recent trading day (a 1.69% change compared to the prior day closing price) with a volume of 2.14M shares and market capitalization of 159.32M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 314 people. ADMA Biologics Inc CEO is Adam S. Grossman.

The one-year performance of ADMA Biologics Inc stock is -48.72%, while year-to-date (YTD) performance is -38.46%. ADMA stock has a five-year performance of -79.31%. Its 52-week range is between 1.15 and 3.1105, which gives ADMA stock a 52-week price range ratio of 2.55%

ADMA Biologics Inc currently has a PE ratio of -1.70, a price-to-book (PB) ratio of 1.42, a price-to-sale (PS) ratio of 2.70, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -34.69%, a ROC of -31.33% and a ROE of -78.11%. The company’s profit margin is -%, its EBITDA margin is -96.60%, and its revenue ttm is $58.11 Million , which makes it $0.44 revenue per share.

Of the last four earnings reports from ADMA Biologics Inc, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.15 for the next earnings report. ADMA Biologics Inc’s next earnings report date is 04th Nov 2021.

The consensus rating of Wall Street analysts for ADMA Biologics Inc is Strong Buy (1.17), with a target price of $7, which is +483.33% compared to the current price. The earnings rating for ADMA Biologics Inc stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ADMA Biologics Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

ADMA Biologics Inc has a Sell technical analysis rating based on Technical Indicators (ADX : 19.08, ATR14 : 0.07, CCI20 : -92.13, Chaikin Money Flow : -0.51, MACD : -0.08, Money Flow Index : 4.82, ROC : -13.04, RSI : 33.00, STOCH (14,3) : 18.52, STOCH RSI : 0.72, UO : 32.36, Williams %R : -81.48), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ADMA Biologics Inc in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (83.33 %)
5 (83.33 %)
5 (71.43 %)
Moderate Buy
1 (16.67 %)
1 (16.67 %)
1 (14.29 %)
Hold
0 (0.00 %)
0 (0.00 %)
1 (14.29 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.17
Strong Buy
1.17
Strong Buy
1.43

ADMA Biologics Inc

ADMA Biologics Inc is a United States-based biopharmaceutical company. It is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The operating segments of the company are ADMA BioManufacturing segment; Plasma Collection Centers segment; and Corporate segment. The Plasma Collection Centers segment consists of three FDA-licensed source plasma collection facilities located in Georgia. The company's ADMA BioManufacturing segment reflects the company's immune globulin manufacturing and development operations in Florida.

CEO: Adam S. Grossman

Telephone: +1 201 478-5552

Address: 465 State Route 17, Ramsey 07446, NJ, US

Number of employees: 314

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

88%13%

Bearish Bullish

56%44%

Bearish Bullish

49%51%

TipRanks News for ADMA

Fri, 13 Aug 2021 11:15 GMT ADMA Biologics (ADMA) Received its Third Buy in a Row

- TipRanks. All rights reserved.

News

Stocktwits